Rafael Holdings' subsidiary Cyclo Therapeutics entered an exclusive licensing agreement with MIT for U.S. Patent No. 12285440 covering cyclodextrins in ApoE4-positive Alzheimer's Disease patients.
Key takeaways
Cyclo Therapeutics, LLC entered exclusive licensing agreement with MIT for U.S. Patent No. 12285440.
Patent covers use of cyclodextrins in Alzheimer's Disease patients with ApoE4 genetic mutation.
License strengthens IP portfolio around Trappsol Cyclo in ApoE4-positive AD population.
ApoE4 variant present in 50-70% of AD patients and key risk factor for early onset sporadic AD.
Preclinical data show Trappsol Cyclo improves cholesterol transport, reduces tau pathology, enhances learning/memory in mice.
Phase 3 results for Trappsol Cyclo in NPC1 expected Q3 2026.